Trade Krystal Biotech, Inc. - KRYS CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.49
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022207 %(-$0.44)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000015 %(-$0.00)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022207 %
  (-$0.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000015 %
  (-$0.00)

Key Stats

• Prev. Close: 344.71
• Open: 345.41
• 1-Year Change: 113.28%
• Day's Range: 341.71 - 347.02

Trade Krystal Biotech, Inc. - KRYS

About Krystal Biotech Inc

Krystal Biotech, Inc. is a clinical stage biotechnology company focused on redosable gene delivery for the treatment of serious rare diseases. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Krystal Biotech Inc revenues was not reported. Net loss increased from $32.2M to $69.6M. Higher net loss reflects General and Administrative - Balancing increase from $12.8M to $30.2M (expense), Stock-based Compensation in SGA increase from $2.3M to $10.2M (expense), Research and Development - Balancing increase of 44% to $24.5M (expense).